Stock Analysis Report

Executive Summary

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products.

Snowflake Analysis

Flawless balance sheet and fair value.

Similar Companies

Share Price & News

How has Spectrum Pharmaceuticals's share price performed over time and what events caused price changes?

Latest Share Price and Events

Stable Share Price: NTR's share price has been volatile over the past 3 months.

Market Performance

7 Day Return




DE Biotechs


DE Market

1 Year Return




DE Biotechs


DE Market

Return vs Industry: NTR underperformed the German Biotechs industry which returned -8.1% over the past year.

Return vs Market: NTR underperformed the German Market which returned -17.5% over the past year.

Shareholder returns

7 Day6.3%11.7%9.9%
30 Day-1.0%-5.9%-16.6%
90 Day-35.0%-22.6%-24.8%
1 Year-78.4%-78.4%-7.9%-8.1%-15.0%-17.5%
3 Year-65.9%-65.9%16.6%15.4%-17.4%-24.5%
5 Year-63.3%-63.3%-6.1%-8.5%-16.6%-28.1%

Price Volatility Vs. Market

How volatile is Spectrum Pharmaceuticals's share price compared to the market and industry in the last 5 years?

Simply Wall St News

No news available


Is Spectrum Pharmaceuticals undervalued compared to its fair value and its price relative to the market?


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: NTR (€2.04) is trading below our estimate of fair value (€36.93)

Significantly Below Fair Value: NTR is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: NTR is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: NTR is unprofitable, so we can't compare its PE Ratio to the German market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NTR's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: NTR is good value based on its PB Ratio (1.3x) compared to the DE Biotechs industry average (3.6x).

Next Steps

Future Growth

How is Spectrum Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NTR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NTR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NTR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NTR's revenue (39.9% per year) is forecast to grow faster than the German market (4.1% per year).

High Growth Revenue: NTR's revenue (39.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NTR's Return on Equity is forecast to be high in 3 years time

Next Steps

Past Performance

How has Spectrum Pharmaceuticals performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NTR is currently unprofitable.

Growing Profit Margin: NTR is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: NTR is unprofitable, and losses have increased over the past 5 years at a rate of -27.6% per year.

Accelerating Growth: Unable to compare NTR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NTR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).

Return on Equity

High ROE: NTR has a negative Return on Equity (-71.11%), as it is currently unprofitable.

Next Steps

Financial Health

How is Spectrum Pharmaceuticals's financial position?

Financial Position Analysis

Short Term Liabilities: NTR's short term assets ($244.0M) exceed its short term liabilities ($62.0M).

Long Term Liabilities: NTR's short term assets ($244.0M) exceed its long term liabilities ($11.1M).

Debt to Equity History and Analysis

Debt Level: NTR is debt free.

Reducing Debt: NTR has no debt compared to 5 years ago when its debt to equity ratio was 37.9%.

Balance Sheet

Inventory Level: NTR has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if NTR's debt is covered by short term assets.

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NTR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NTR has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of -37.2% each year.

Next Steps


What is Spectrum Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NTR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate NTR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NTR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NTR's dividend payments have been increasing.

Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NTR's dividend in 3 years as they are not forecast to pay a notable one for the German market.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Joe Turgeon (61yo)





Mr. Joseph W. Turgeon, also known as Joe, has been the President of Spectrum Pharmaceuticals, Inc. since April 2014 and its Chief Executive Officer since December 17, 2017. Mr. Turgeon served as the Chief  ...

CEO Compensation Analysis

Compensation vs Market: Joe's total compensation ($USD4.72M) is above average for companies of similar size in the German market ($USD731.58K).

Compensation vs Earnings: Joe's compensation has increased whilst the company is unprofitable.

Leadership Team

Joseph Turgeon
President2.25yrsUS$4.72m0.62% $1.4m
Kurt Gustafson
Executive VP6.67yrsUS$2.59m0.34% $785.2k
Thomas Riga
Executive VP2.25yrsUS$5.30m0.39% $901.8k
Keith McGahan
Senior VP1.67yrsUS$5.08m0.26% $610.3k
Shivpreet Kapoor
Vice President of Strategic Planning & Investor Relationsno datano datano data
Bimal Shah
Vice President of Corporate & Business Developmentno datano datano data
Alberto Dejesus
Vice President of Marketingno datano datano data
Lisa Croissant
Vice President of Salesno datano datano data
Zane Yang
Senior Vice President of Clinical Development3.42yrsno datano data
Michael Grabow
Senior Vice President of Corporate Strategy & Operations2yrsno datano data


Average Tenure


Average Age

Experienced Management: NTR's management team is considered experienced (2.3 years average tenure).

Board Members

Joseph Turgeon
President2.25yrsUS$4.72m0.62% $1.4m
Raymond Cohen
Independent Director6.67yrsUS$483.22k0.048% $111.2k
Bernice Welles
Independent Director1.67yrsUS$420.72k0.018% $41.3k
Elizabeth Czerepak
Independent Director0.67yrno data0.0089% $20.7k
William Ashton
Independent Chairman of the Board0.67yrUS$544.50k0.015% $34.4k
Dolatrai Vyas
Independent Director6.67yrsUS$458.22k0.046% $105.5k
Jeffrey Vacirca
Independent Director1.25yrsUS$213.94k0.029% $66.0k


Average Tenure


Average Age

Experienced Board: NTR's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7%.

Top Shareholders

Company Information

Spectrum Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources

Key Information

  • Name: Spectrum Pharmaceuticals, Inc.
  • Ticker: NTR
  • Exchange: DB
  • Founded: 1987
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$254.308m
  • Listing Market Cap: US$231.421m
  • Shares outstanding: 112.03m
  • Website: https://www.sppirx.com

Number of Employees


  • Spectrum Pharmaceuticals, Inc.
  • 11500 South Eastern Avenue
  • Suite 240
  • Henderson
  • Nevada
  • 89052
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SPPINasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDSep 1996
NTRDB (Deutsche Boerse AG)YesCommon SharesDEEURSep 1996
NTRBRSE (Berne Stock Exchange)YesCommon SharesCHCHFSep 1996


Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company offers KHAPZORY, a novel folate analog and the pharmacologically active levo-isomer of d, and 1-leucovorin; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection to treat non-Hodgkin’s lymphoma; MARQIBO for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ, a histone deacytelase, or HDAC, inhibitor for the treatment of patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB, a pan-HER inhibitor for non-small cell lung cancer tumors; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly to hospitals and cancer centers in the United States; and through distributors in Europe. It has a strategic partnership with Servier Canada, Inc.; licensing and development agreement with Cell Therapeutics, Inc.; license agreements with Merck & Cie AG, Medac Pharma, Inc., Sloan-Kettering Institute for Cancer Research, SRI International, Southern Research Institute, Medac Pharma, Inc., Cydex Pharmaceuticals, Inc., and Mundipharma International Corporation Limited; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreements with Hanmi Pharmaceutical Co. Ltd and The University of Texas MD Anderson Cancer Center. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada. 

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/31 21:41
End of Day Share Price2020/03/31 00:00
Annual Earnings2019/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.